Showing papers by "Günther G. Steger published in 2021"
TL;DR: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumabs (CLEOPATRA) trial established the combination of pertuzumaab, trastuzumaba and docetaxel as standard first-line therapy for locally recurrent/metastatic breast cancer (LR/mBC).
21 citations
University of Pittsburgh1, Hospital General Universitario Gregorio Marañón2, Harvard University3, Fudan University4, University of Erlangen-Nuremberg5, National Taiwan University6, Mayo Clinic7, University of California, San Francisco8, Gdańsk Medical University9, University of Genoa10, Medical University of Vienna11, Hochschule Hannover12, Yonsei University13, University of Padua14, European University of Madrid15, Sarah Cannon Research Institute16, Eli Lilly and Company17, Kyoto University18, Baylor University Medical Center19
TL;DR: Abemaciclibel combined with endocrine therapy (ET) showed clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse free survival (DRFS) in HR+, HER2-, node-positive, high risk early breast cancer (EBC) at the second interim analysis, however follow-up was limited as mentioned in this paper.
8 citations
Journal Article•
6 citations
TL;DR: In this article, after extravasation of cytotoxic vesicants, anthracyclines were determined in removed tissue from patients requiring surgical intervention due to tissue necrosis.
Abstract: As critical parameter after extravasation of cytotoxic vesicants, anthracyclines were determined in removed tissue from patients requiring surgical intervention due to tissue necrosis. We monitored their distribution within the affected lesion to establish a possible dose–toxicity relation. From six patients scheduled for surgery, removed tissue flaps were systematically analysed by HPLC (epirubicin: 5 subjects; doxorubicin: 1 subject). After extravasation, tissue concentrations were highly variable with an individual anthracycline distribution pattern ranging from a few nanograms up to 17 µg per 100 mg tissue, which indicated a substantial difference in tissue sensitivity among patients. The resection borders coincided with the extension of the erythema and guided the surgical intervention after demarcation of the lesion, which occurred usually 2 or 3 weeks after extravasation. At that time, drug was hardly detected at the resection borders. Wound drains were negative for the extravasated drugs while showing a time profile of vascular growth factors and inflammatory cytokines, which was highly similar to routine surgery. In all six patients, surgical debridement with immediate wound closure led to healing within approximately 2 weeks, when therapy was resumed in all patients with reasonable time delay. Surgical intervention after demarcation of the extravasation lesion allows for almost uninterrupted continuation of treatment independent of the amount of extravasated anthracycline. As even minor amounts of the vesicants may trigger tissue necrosis, preventive measures merit the highest priority.